Immutep says EFTISARC-NEO Phase II ePoster on efti HRQoL in soft tissue sarcoma accepted for ESMO 2026

• Immutep flagged an accepted ESMO Congress 2026 ePoster from the Phase II EFTISARC-NEO trial of eftilagimod alfa in soft tissue sarcoma.
• Results have not been presented yet; the abstract is scheduled to post online Oct. 19, 2026, ahead of the Oct. 23-27 meeting.
• The readout focuses on patient-reported quality of life during neoadjuvant treatment combining eftilagimod alfa with pembrolizumab and radiotherapy.
• The update signals continued clinical momentum for efti, with investor attention likely on tolerability and treatment experience alongside efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240800PRIMZONEFULLFEED9767538) on July 24, 2026, and is solely responsible for the information contained therein.